Cargando…

Induced pluripotent stem cell-based therapies for organ fibrosis

Fibrotic diseases result in organ remodelling and dysfunctional failure and account for one-third of all deaths worldwide. There are no ideal treatments that can halt or reverse progressive organ fibrosis, moreover, organ transplantation is complicated by problems with a limited supply of donor orga...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wei, Fan, Chengming, Song, Qing, Chen, Ping, Peng, Hong, Lin, Ling, Liu, Cong, Wang, Bin, Zhou, Zijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232908/
https://www.ncbi.nlm.nih.gov/pubmed/37274156
http://dx.doi.org/10.3389/fbioe.2023.1119606
_version_ 1785052104734277632
author Cheng, Wei
Fan, Chengming
Song, Qing
Chen, Ping
Peng, Hong
Lin, Ling
Liu, Cong
Wang, Bin
Zhou, Zijing
author_facet Cheng, Wei
Fan, Chengming
Song, Qing
Chen, Ping
Peng, Hong
Lin, Ling
Liu, Cong
Wang, Bin
Zhou, Zijing
author_sort Cheng, Wei
collection PubMed
description Fibrotic diseases result in organ remodelling and dysfunctional failure and account for one-third of all deaths worldwide. There are no ideal treatments that can halt or reverse progressive organ fibrosis, moreover, organ transplantation is complicated by problems with a limited supply of donor organs and graft rejection. The development of new approaches, especially induced pluripotent stem cell (iPSC)-based therapy, is becoming a hot topic due to their ability to self-renew and differentiate into different cell types that may replace the fibrotic organs. In the past decade, studies have differentiated iPSCs into fibrosis-relevant cell types which were demonstrated to have anti-fibrotic effects that may have the potential to inform new effective precision treatments for organ-specific fibrosis. In this review, we summarize the potential of iPSC-based cellular approaches as therapeutic avenues for treating organ fibrosis, the advantages and disadvantages of iPSCs compared with other types of stem cell-based therapies, as well as the challenges and future outlook in this field.
format Online
Article
Text
id pubmed-10232908
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102329082023-06-02 Induced pluripotent stem cell-based therapies for organ fibrosis Cheng, Wei Fan, Chengming Song, Qing Chen, Ping Peng, Hong Lin, Ling Liu, Cong Wang, Bin Zhou, Zijing Front Bioeng Biotechnol Bioengineering and Biotechnology Fibrotic diseases result in organ remodelling and dysfunctional failure and account for one-third of all deaths worldwide. There are no ideal treatments that can halt or reverse progressive organ fibrosis, moreover, organ transplantation is complicated by problems with a limited supply of donor organs and graft rejection. The development of new approaches, especially induced pluripotent stem cell (iPSC)-based therapy, is becoming a hot topic due to their ability to self-renew and differentiate into different cell types that may replace the fibrotic organs. In the past decade, studies have differentiated iPSCs into fibrosis-relevant cell types which were demonstrated to have anti-fibrotic effects that may have the potential to inform new effective precision treatments for organ-specific fibrosis. In this review, we summarize the potential of iPSC-based cellular approaches as therapeutic avenues for treating organ fibrosis, the advantages and disadvantages of iPSCs compared with other types of stem cell-based therapies, as well as the challenges and future outlook in this field. Frontiers Media S.A. 2023-05-18 /pmc/articles/PMC10232908/ /pubmed/37274156 http://dx.doi.org/10.3389/fbioe.2023.1119606 Text en Copyright © 2023 Cheng, Fan, Song, Chen, Peng, Lin, Liu, Wang and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Cheng, Wei
Fan, Chengming
Song, Qing
Chen, Ping
Peng, Hong
Lin, Ling
Liu, Cong
Wang, Bin
Zhou, Zijing
Induced pluripotent stem cell-based therapies for organ fibrosis
title Induced pluripotent stem cell-based therapies for organ fibrosis
title_full Induced pluripotent stem cell-based therapies for organ fibrosis
title_fullStr Induced pluripotent stem cell-based therapies for organ fibrosis
title_full_unstemmed Induced pluripotent stem cell-based therapies for organ fibrosis
title_short Induced pluripotent stem cell-based therapies for organ fibrosis
title_sort induced pluripotent stem cell-based therapies for organ fibrosis
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232908/
https://www.ncbi.nlm.nih.gov/pubmed/37274156
http://dx.doi.org/10.3389/fbioe.2023.1119606
work_keys_str_mv AT chengwei inducedpluripotentstemcellbasedtherapiesfororganfibrosis
AT fanchengming inducedpluripotentstemcellbasedtherapiesfororganfibrosis
AT songqing inducedpluripotentstemcellbasedtherapiesfororganfibrosis
AT chenping inducedpluripotentstemcellbasedtherapiesfororganfibrosis
AT penghong inducedpluripotentstemcellbasedtherapiesfororganfibrosis
AT linling inducedpluripotentstemcellbasedtherapiesfororganfibrosis
AT liucong inducedpluripotentstemcellbasedtherapiesfororganfibrosis
AT wangbin inducedpluripotentstemcellbasedtherapiesfororganfibrosis
AT zhouzijing inducedpluripotentstemcellbasedtherapiesfororganfibrosis